

Tumor Profiling

NGS Panels

Next-generation sequencing for comprehensive mutation analysis

TMB Assessment

Tumor Mutational Burden predicts immunotherapy response

MSI Status

Microsatellite Instability as biomarker for treatment selection

HRD Testing

Homologous Recombination Deficiency guides PARP inhibitor use

PD-L1 Expression: Key biomarker for immune checkpoint inhibitor therapy eligibility